Advertisement

Journal of Molecular Medicine

, Volume 97, Issue 2, pp 243–255 | Cite as

Cancer-associated fibroblasts promote the stemness of CD24+ liver cells via paracrine signaling

  • Yawen Li
  • Ronghua WangEmail author
  • Si Xiong
  • Xiju Wang
  • Zhenxiong Zhao
  • Shuya Bai
  • Yun Wang
  • Yuchong Zhao
  • Bin ChengEmail author
Original Article
  • 198 Downloads

Abstract

Cancer stem cells (CSCs), which support tumor progress in hepatocellular carcinoma (HCC) developed in fibrotic or cirrhotic livers, are regulated by the tumor microenvironment. Cancer-associated fibroblasts (CAFs) are the major component of the tumor stroma in HCC; however, the mechanisms by which CAFs contribute to stemness maintenance remain largely unknown. Here, we found that the expression of CD24 was high in HCC tissues compared with adjacent normal liver tissues, and positively correlated with the poor prognosis and α-SMA expression in CAFs. CD24+ cells isolated from HCC cell lines exhibited stemness properties of self-renewal, chemotherapy resistance, metastasis, and tumorigenicity in NOD/SCID mice. Moreover, CAF-derived HGF and IL6 enhanced the stemness properties of CD24+ cells via activating STAT3 Tyr705 phosphorylation. Blockade of HGF/c-Met or IL6/IL6R signaling significantly abolished the effect of CAFs on stemness properties, which compromised the activation of STAT3 pathway in CD24+ cells. Meanwhile, knockdown of STAT3 in CD24+ cells notably attenuated CAF-induced stemness characteristics of CD24+ cells. Furthermore, in HCC patients, higher expression of phospho-STAT3 was also demonstrated to be positively correlated with poor clinical outcomes. In summary, HGF and IL6 secreted by CAFs promoted the stemness properties of CD24+ cells through the phosphorylation of STAT3 signaling, and targeting the paracrine pathways may provide a new therapeutic strategy for HCC.

Key messages

  • CD24, identified as a marker for HCC CSCs, was positively correlated with the poor prognosis and α-SMA expression in CAFs.

  • CAFs promoted self-renewal, chemotherapy resistance, metastasis, and tumorigenicity of CD24+ HCC cells.

  • HGF and IL6 secreted by CAFs promoted the stemness properties of CD24+ HCC cells through the phosphorylation of STAT3.

Keywords

Cancer stem cell Cancer-associated fibroblasts Hepatocellular carcinoma Interleukin-6 Hepatocyte growth factor STAT3 

Notes

Funding information

This work was supported by grants from the National Natural Science Foundation of China (81172063 and 81372352).

Compliance with ethical standards

All human studies were approved by the Ethical Committee of Tongji Hospital, Huazhong University of Science and Technology (HUST, Wuhan, China) (IRB ID: TJ-C20160117) and informed consent was obtained from each patient. The animal studies were conducted according to Tongji Hospital Institutional Review Board Approval of Experimental Animals (IRB ID: TJ-A20161205).

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

109_2018_1731_MOESM1_ESM.jpg (7.7 mb)
ESM 1 (JPG 7928 kb)
109_2018_1731_MOESM2_ESM.jpg (7.8 mb)
ESM 2 (JPG 7990 kb)
109_2018_1731_MOESM3_ESM.docx (8.1 mb)
ESM 3 (DOCX 8248 kb)

References

  1. 1.
    Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, Gores G (2016) Hepatocellular carcinoma. Nat Rev Dis Primers 2:16018CrossRefGoogle Scholar
  2. 2.
    Magee JA, Piskounova E, Morrison SJ (2012) Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 21:283–296CrossRefGoogle Scholar
  3. 3.
    Yamashita T, Wang XW (2013) Cancer stem cells in the development of liver cancer. J Clin Invest 123:1911–1918CrossRefGoogle Scholar
  4. 4.
    Ooki A, VandenBussche CJ, Kates M, Hahn NM, Matoso A, McConkey DJ, Bivalacqua TJ, Hoque MO (2018) CD24 regulates cancer stem cell (CSC)-like traits and a panel of CSC-related molecules serves as a non-invasive urinary biomarker for the detection of bladder cancer. Br J Cancer 119:961–970CrossRefGoogle Scholar
  5. 5.
    Yang XR, Xu Y, Yu B, Zhou J, Li JC, Qiu SJ, Shi YH, Wang XY, Dai Z, Shi GM, Wu B, Wu LM, Yang GH, Zhang BH, Qin WX, Fan J (2009) CD24 is a novel predictor for poor prognosis of hepatocellular carcinoma after surgery. Clin Cancer Res 15:5518–5527CrossRefGoogle Scholar
  6. 6.
    Korkaya H, Liu S, Wicha MS (2011) Breast cancer stem cells, cytokine networks, and the tumor microenvironment. J Clin Invest 121:3804–3809CrossRefGoogle Scholar
  7. 7.
    Medema JP, Vermeulen L (2011) Microenvironmental regulation of stem cells in intestinal homeostasis and cancer. Nature 474:318–326CrossRefGoogle Scholar
  8. 8.
    Hanahan D, Coussens LM (2012) Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21:309–322CrossRefGoogle Scholar
  9. 9.
    Xing F, Saidou J, Watabe K (2010) Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front Biosci 15:166–179CrossRefGoogle Scholar
  10. 10.
    Affo S, Yu LX, Schwabe RF (2017) The role of cancer-associated fibroblasts and fibrosis in liver cancer. Annu Rev Pathol 12:153–186CrossRefGoogle Scholar
  11. 11.
    Kalluri R (2016) The biology and function of fibroblasts in cancer. Nat Rev Cancer 16:582–598CrossRefGoogle Scholar
  12. 12.
    Liu J, Chen S, Wang W, Ning BF, Chen F, Shen W, Ding J, Chen W, Xie WF, Zhang X (2016) Cancer-associated fibroblasts promote hepatocellular carcinoma metastasis through chemokine-activated hedgehog and TGF-beta pathways. Cancer Lett 379:49–59CrossRefGoogle Scholar
  13. 13.
    Tsuyada A, Chow A, Wu J, Somlo G, Chu PG, Loera S, Luu TH, Li AXJ, Wu XW, Ye W, Chen SA, Zhou WY, Yu Y, Wang YZ, Ren XB, Li H, Scherle P, Kuroki Y, Wang SE (2012) CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells. Cancer Res 72:2768–2779CrossRefGoogle Scholar
  14. 14.
    Jia CC, Wang TT, Liu W, Fu BS, Hua X, Wang GY, Li TJ, Li X, Wu XY, Tai Y, Zhou J, Chen GH, Zhang Q (2013) Cancer-associated fibroblasts from hepatocellular carcinoma promote malignant cell proliferation by HGF secretion. PLoS One 8:e63243CrossRefGoogle Scholar
  15. 15.
    Wu X, Tao P, Zhou Q, Li J, Yu Z, Wang X, Li J, Li C, Yan M, Zhu Z, Liu B, Su L (2017) IL-6 secreted by cancer-associated fibroblasts promotes epithelial-mesenchymal transition and metastasis of gastric cancer via JAK2/STAT3 signaling pathway. Oncotarget 8:20741–20750Google Scholar
  16. 16.
    Luo J, Wang P, Wang R, Wang J, Liu M, Xiong S, Li Y, Cheng B (2016) The notch pathway promotes the cancer stem cell characteristics of CD90+ cells in hepatocellular carcinoma. Oncotarget 7:9525–9537Google Scholar
  17. 17.
    Scheel C, Eaton EN, Li SH, Chaffer CL, Reinhardt F, Kah KJ, Bell G, Guo W, Rubin J, Richardson AL, Weinberg RA (2011) Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell 145:926–940CrossRefGoogle Scholar
  18. 18.
    Xiong SWR, Chen Q, Luo J, Wang J, Zhao Z, Li Y, Wang Y, Wang X, Cheng B (2018) Cancer-associated fibroblasts promote stem cell-like properties of hepatocellular carcinoma cells through IL-6/STAT3/notch signaling. Am J Cancer Res 8:302–316Google Scholar
  19. 19.
    Schmidt-Arras D, Rose-John S (2016) IL-6 pathway in the liver: from physiopathology to therapy. J Hepatol 64:1403–1415CrossRefGoogle Scholar
  20. 20.
    Trusolino L, Bertotti A, Comoglio PM (2010) MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 11:834–848CrossRefGoogle Scholar
  21. 21.
    Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, Emery P, Raemen F, Petersen J, Smolen J, Thomson D, Kishimoto T, Group CS (2006) Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54:2817–2829CrossRefGoogle Scholar
  22. 22.
    Gupta PB, Chaffer CL, Weinberg RA (2009) Cancer stem cells: mirage or reality? Nat Med 15:1010–1012CrossRefGoogle Scholar
  23. 23.
    Liu AY, Cai Y, Mao Y, Lin Y, Zheng H, Wu T, Huang Y, Fang X, Lin S, Feng Q, Huang Z, Yang T, Luo Q, Ouyang G (2014) Twist2 promotes self-renewal of liver cancer stem-like cells by regulating CD24. Carcinogenesis 35:537–545CrossRefGoogle Scholar
  24. 24.
    Lee TK, Castilho A, Cheung VC, Tang KH, Ma S, Ng IO (2011) CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. Cell Stem Cell 9:50–63CrossRefGoogle Scholar
  25. 25.
    Su S, Chen J, Yao H, Liu J, Yu S, Lao L, Wang M, Luo M, Xing Y, Chen F, Huang D, Zhao J, Yang L, Liao D, Su F, Li M, Liu Q, Song E (2018) CD10(+)GPR77(+) cancer-associated fibroblasts promote cancer formation and chemoresistance by sustaining cancer stemness. Cell 172(841–856):e816Google Scholar
  26. 26.
    Lau EY, Lo J, Cheng BY, Ma MK, Lee JM, Ng JK, Chai S, Lin CH, Tsang SY, Ma S, Ng IO, Lee TK (2016) Cancer-associated fibroblasts regulate tumor-initiating cell plasticity in hepatocellular carcinoma through c-met/FRA1/HEY1 signaling. Cell Rep 15:1175–1189CrossRefGoogle Scholar
  27. 27.
    Qin X, Yan M, Wang X, Xu Q, Wang X, Zhu X, Shi J, Li Z, Zhang J, Chen W (2018) Cancer-associated fibroblast-derived IL-6 promotes head and neck cancer progression via the osteopontin-NF-kappa B signaling pathway. Theranostics 8:921–940CrossRefGoogle Scholar
  28. 28.
    Bai YP, Shang K, Chen H, Ding F, Wang Z, Liang C, Xu Y, Sun MH, Li YY (2015) FGF-1/−3/FGFR4 signaling in cancer-associated fibroblasts promotes tumor progression in colon cancer through Erk and MMP-7. Cancer Sci 106:1278–1287CrossRefGoogle Scholar
  29. 29.
    Hasegawa T, Yashiro M, Nishii T, Matsuoka J, Fuyuhiro Y, Morisaki T, Fukuoka T, Shimizu K, Shimizu T, Miwa A, Hirakawa K (2014) Cancer-associated fibroblasts might sustain the stemness of scirrhous gastric cancer cells via transforming growth factor-beta signaling. Int J Cancer 134:1785–1795CrossRefGoogle Scholar
  30. 30.
    Teng F, Tian WY, Wang YM, Zhang YF, Guo F, Zhao J, Gao C, Xue FX (2016) Cancer-associated fibroblasts promote the progression of endometrial cancer via the SDF-1/CXCR4 axis. J Hematol Oncol 9:8CrossRefGoogle Scholar
  31. 31.
    Owusu BY, Galemmo R, Janetka J, Klampfer L (2017) Hepatocyte growth factor, a key tumor-promoting factor in the tumor microenvironment. Cancers (Basel) 9:Google Scholar
  32. 32.
    Vermeulen L, De Sousa EMF, van der Heijden M, Cameron K, de Jong JH, Borovski T, Tuynman JB, Todaro M, Merz C, Rodermond H, Sprick MR, Kemper K, Richel DJ, Stassi G, Medema JP (2010) Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 12:468–476CrossRefGoogle Scholar
  33. 33.
    Johnson DE, O'Keefe RA, Grandis JR (2018) Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol 15:234–248CrossRefGoogle Scholar
  34. 34.
    Wan S, Zhao E, Kryczek I, Vatan L, Sadovskaya A, Ludema G, Simeone DM, Zou W, Welling TH (2014) Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells. Gastroenterology 147:1393–1404CrossRefGoogle Scholar
  35. 35.
    Lim YC, Kang HJ, Moon JH (2014) C-Met pathway promotes self-renewal and tumorigenecity of head and neck squamous cell carcinoma stem-like cell. Oral Oncol 50:633–639CrossRefGoogle Scholar
  36. 36.
    You H, Ding W, Dang H, Jiang Y, Rountree CB (2011) c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma. Hepatology 54:879–889CrossRefGoogle Scholar
  37. 37.
    Giordano S, Columbano A (2014) Met as a therapeutic target in HCC: facts and hopes. J Hepatol 60:442–452CrossRefGoogle Scholar
  38. 38.
    Wang CQ, Sun HT, Gao XM, Ren N, Sheng YY, Wang Z, Zheng Y, Wei JW, Zhang KL, Yu XX, Zhu Y, Luo Q, Yang LY, Dong QZ, Qin LX (2016) Interleukin-6 enhances cancer stemness and promotes metastasis of hepatocellular carcinoma via up-regulating osteopontin expression. Am J Cancer Res 6:1873–1889Google Scholar
  39. 39.
    Zheng X, Xu M, Yao B, Wang C, Jia Y, Liu Q (2016) IL-6/STAT3 axis initiated CAFs via up-regulating TIMP-1 which was attenuated by acetylation of STAT3 induced by PCAF in HCC microenvironment. Cell Signal 28:1314–1324CrossRefGoogle Scholar
  40. 40.
    Zhu Q, Zhang X, Zhang L, Li W, Wu H, Yuan X, Mao F, Wang M, Zhu W, Qian H, Xu W (2014) The IL-6-STAT3 axis mediates a reciprocal crosstalk between cancer-derived mesenchymal stem cells and neutrophils to synergistically prompt gastric cancer progression. Cell Death Dis 5:e1295CrossRefGoogle Scholar
  41. 41.
    Thiagarajan PS, Zheng Q, Bhagrath M, Mulkearns-Hubert EE, Myers MG, Lathia JD, Reizes O (2017) STAT3 activation by leptin receptor is essential for TNBC stem cell maintenance. Endocr Relat Cancer 24:415–426CrossRefGoogle Scholar
  42. 42.
    Wang H, Huo X, Yang XR, He J, Cheng L, Wang N, Deng X, Jin H, Wang N, Wang C, Zhao F, Fang J, Yao M, Fan J, Qin W (2017) STAT3-mediated upregulation of lncRNA HOXD-AS1 as a ceRNA facilitates liver cancer metastasis by regulating SOX4. Mol Cancer 16:136CrossRefGoogle Scholar
  43. 43.
    Jiang C, Long J, Liu B, Xu M, Wang W, Xie X, Wang X, Kuang M (2017) miR-500a-3p promotes cancer stem cells properties via STAT3 pathway in human hepatocellular carcinoma. J Exp Clin Cancer Res 36:99CrossRefGoogle Scholar
  44. 44.
    Lin L, Fuchs J, Li C, Olson V, Bekaii-Saab T, Lin J (2011) STAT3 signaling pathway is necessary for cell survival and tumorsphere forming capacity in ALDH(+)/CD133(+) stem cell-like human colon cancer cells. Biochem Biophys Res Commun 416:246–251CrossRefGoogle Scholar
  45. 45.
    Sherry MMRA, Wu JK, Cochran BH (2009) STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. Stem Cells 27:2383–2392CrossRefGoogle Scholar
  46. 46.
    Ma Z, He H, Sun F, Xu Y, Huang X, Ma Y, Zhao H, Wang Y, Wang M, Zhang J (2017) Selective targeted delivery of doxorubicin via conjugating to anti-CD24 antibody results in enhanced antitumor potency for hepatocellular carcinoma both in vitro and in vivo. J Cancer Res Clin Oncol 143:1929–1940CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Yawen Li
    • 1
  • Ronghua Wang
    • 1
    Email author
  • Si Xiong
    • 1
  • Xiju Wang
    • 1
  • Zhenxiong Zhao
    • 1
  • Shuya Bai
    • 1
  • Yun Wang
    • 1
  • Yuchong Zhao
    • 1
  • Bin Cheng
    • 1
    Email author
  1. 1.Department of Gastroenterology and Hepatology, Tongji Hospital, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina

Personalised recommendations